Category Archives: Cell Biology

Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry – PRNewswire

DUBLIN, Aug. 11, 2020 /PRNewswire/ -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.

Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its off-the-shelf iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.

iPS Cell Commercialization

Methods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand. iPSC cell applications include, but are not limited to:

Since the discovery of iPSC technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.

Key Topics Covered:

1. Report Overview

2. Introduction

3. History of Induced Pluripotent Stem Cells (IPSCS)

4. Research Publications on IPSCS

5. IPSCS: Patent Landscape

6. Clinical Trials Involving IPSCS

7. Funding for IPSC

8. Generation of Induced Pluripotent Stem Cells: An Overview

9. Human IPSC Banking

10. Biomedical Applications of IPSCS

11. Other Novel Applications of IPSCS

12. Deals in the IPSCS Sector

13. Market Overview

14. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/kpc95y

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original:
Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire

REGULUS THERAPEUTICS : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19…

The interim unaudited condensed financial statements and this Management'sDiscussion and Analysis of Financial Condition and Results of Operations shouldbe read in conjunction with the financial statements and notes thereto for theyear ended December 31, 2019 and the related Management's Discussion andAnalysis of Financial Condition and Results of Operations, both of which arecontained in our Annual Report on Form 10-K for the year ended December 31,2019, or Annual Report, filed with the Securities and Exchange Commission onMarch 12, 2020. Past operating results are not necessarily indicative of resultsthat may occur in future periods.FORWARD-LOOKING STATEMENTSThis quarterly report on Form 10-Q contains "forward-looking statements" withinthe meaning of federal securities laws made pursuant to the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Our actualresults could differ materially from those anticipated in these forward-lookingstatements as a result of various factors, including those set forth below underPart II, Item 1A, "Risk Factors" in this quarterly report on Form 10-Q. Exceptas required by law, we assume no obligation to update these forward-lookingstatements, whether as a result of new information, future events or otherwise.These statements, which represent our current expectations or beliefs concerningvarious future events, may contain words such as "may," "will," "expect,""anticipate," "intend," "plan," "believe," "estimate" or other words indicatingfuture results, though not all forward-looking statements necessarily containthese identifying words. Such statements may include, but are not limited to,statements concerning the following:the initiation, cost, timing, progress and results of, and our expected abilityto undertake certain activities and accomplish certain goals with respect to ourresearch and development activities, preclinical studies and clinical trials;our ability to obtain and maintain regulatory approval of our productcandidates, and any related restrictions, limitations, and/or warnings in thelabel of an approved product candidate;our ability to obtain funding for our operations;our plans to research, develop and commercialize our product candidates;the potential election of any strategic collaboration partner to pursuedevelopment and commercialization of any programs or product candidates that aresubject to a collaboration with such partner;our ability to attract collaborators with relevant development, regulatory andcommercialization expertise;future activities to be undertaken by our strategic collaboration partners,collaborators and other third parties;our ability to obtain and maintain intellectual property protection for ourproduct candidates;the size and growth potential of the markets for our product candidates, andour ability to serve those markets;our ability to successfully commercialize, and our expectations regardingfuture therapeutic and commercial potential with respect to our productcandidates;the rate and degree of market acceptance of our product candidates;our ability to develop sales and marketing capabilities, whether alone or withpotential future collaborators;regulatory developments in the United States and foreign countries;the performance of our third-party suppliers and manufacturers;the success of competing therapies that are or may become available;the loss of key scientific or management personnel;our ability to successfully secure and deploy capital;our ability to satisfy our debt obligations;the accuracy of our estimates regarding future expenses, future revenues,capital requirements and need for additional financing;the potential impact of the COVID-19 pandemic on our business; andthe risks and other forward-looking statements described under the caption"Risk Factors" under Part II, Item 1A of this quarterly report on Form 10-Q.In addition, statements that "we believe" and similar statements reflect ourbeliefs and opinions on the relevant subject. These statements are based uponinformation available to us as of the date of this report, and while we believesuch information 20--------------------------------------------------------------------------------forms a reasonable basis for such statements, such information may be limited orincomplete, and our statements should not be read to indicate that we haveconducted an exhaustive inquiry into, or review of, all potentially availablerelevant information. These statements are inherently uncertain and investorsare cautioned not to unduly rely upon these statements.OVERVIEWWe are a clinical-stage biopharmaceutical company focused on discovering anddeveloping first-in-class drugs targeting microRNAs to treat diseases withsignificant unmet medical need. We were formed in 2007 when AlnylamPharmaceuticals, Inc. ("Alnylam") and Ionis Pharmaceuticals, Inc. ("Ionis")contributed significant intellectual property, know-how and financial and humancapital to pursue the development of drugs targeting microRNAs pursuant to alicense and collaboration agreement. Our most advanced product candidates areRG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment ofAlport syndrome, a life-threatening kidney disease with no approved therapyavailable. In November 2018, we and Sanofi agreed to transition furtherdevelopment activities of our miR-21 programs, including our RG-012 program. Asa result, Sanofi became responsible for all costs incurred in the development ofRG-012 and any other miR-21 programs. The transition activities were completedin the second quarter of 2019. RGLS4326 is an anti-miR targeting miR-17 for thetreatment of autosomal dominant polycystic kidney disease ("ADPKD"). In additionto these clinical programs, we continue to develop a pipeline of preclinicaldrug product candidates.microRNAs are naturally occurring ribonucleic acid ("RNA") molecules that play acritical role in regulating key biological pathways. Scientific research hasshown that an imbalance, or dysregulation, of microRNAs is directly linked tomany diseases. Furthermore, many different infectious pathogens interact andbind to host microRNA to survive. To date, over 500 microRNAs have beenidentified in humans, each of which can bind to multiple messenger RNAs thatcontrol key aspects of cell biology. Since many diseases are multi-factorial,involving multiple targets and pathways, the ability to modulate multiplepathways by targeting a single microRNA provides a new therapeutic approach fortreating complex diseases.RNA plays an essential role in the process used by cells to encode and translategenetic information from deoxyribonucleic acid, or DNA, to proteins. RNA iscomprised of subunits called nucleotides and is synthesized from a DNA templateby a process known as transcription. Transcription generates different types ofRNA, including messenger RNAs that carry the information for proteins in thesequence of their nucleotides. In contrast, microRNAs are RNAs that do not codefor proteins but rather are responsible for regulating gene expression bymodulating the translation and decay of target messenger RNAs. By interactingwith many messenger RNAs, a single microRNA can regulate the expression ofmultiple genes involved in the normal function of a biological pathway. Manypathogens, including viruses, bacteria and parasites, also use host microRNAs toregulate the cellular environment for survival. In some instances, the hostmicroRNAs are essential for the replication and/or survival of the pathogen. Forexample, miR-122 is a microRNA expressed in human hepatocytes and is a keyfactor for the replication of the hepatitis C virus ("HCV").We believe that microRNA therapeutics have the potential to become a new andmajor class of drugs with broad therapeutic application for the followingreasons:microRNAs play a critical role in regulating biological pathways by controllingthe translation of many target genes;microRNA therapeutics regulate disease pathways which may result in moreeffective treatment of complex multi-factorial diseases;many human pathogens, including viruses, bacteria and parasites, use microRNAs(host and pathogen encoded) to enable their replication and suppression of hostimmune responses; andmicroRNA therapeutics may be synergistic with other therapies because of theirdifferent mechanism of action.We have assembled significant expertise in the microRNA field, includingexpertise in microRNA biology and oligonucleotide chemistry, a broadintellectual property estate, relationships with key opinion leaders and adisciplined drug discovery and development process. We are using our microRNAexpertise to develop chemically modified, single-stranded oligonucleotides thatwe call anti-miRs to modulate microRNAs and address underlying disease. Webelieve microRNAs may play a critical role in complex disease and that targetingthem with anti-miRs may become a source of a new and major class of drugs withbroad therapeutic application, much like small molecules, biologics andmonoclonal antibodies.We believe that microRNA biomarkers may be used to select optimal patientsegments in clinical trials and to monitor disease progression or relapse. Webelieve these microRNA biomarkers can be applied toward drugs that we developand drugs developed by other companies with which we partner or collaborate. 21--------------------------------------------------------------------------------Since our inception through June 30, 2020, we have received $342.5 million fromthe sale of our equity and convertible debt securities, $91.8 million from ourstrategic collaborations, principally from upfront payments, research fundingand preclinical and clinical milestones, and $19.8 million in net proceeds fromour Term Loan. As of June 30, 2020, we had cash and cash equivalents of $23.4million.Development Stage Pipeline

We currently have two programs in clinical development.

Preclinical Pipeline

We currently have multiple programs in various stages of preclinicaldevelopment.

18 $ 6$ 6,796Research and development expenses

The following table shows a summary of our cash flows for the six months endedJune 30, 2020 and 2019 (in thousands):

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

See the original post here:
REGULUS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19...

Doctoral Student/Research Assistant in Mitochondrial Biology and Signalling job with UNIVERSITY OF HELSINKI | 218596 – Times Higher Education (THE)

The University of Helsinki as research-oriented university offers a stimulating and international environment. The Faculty of Medicine of the University of Helsinki, together with Helsinki University Central Hospital, The Helsinki Institute of Life Science, and the Institute for Molecular Medicine Finland forms the Academic Medical Center Helsinki. This medical campus ranks among the 10 best medical centers at European level and the 50 best centers in the world. More info on the Faculty or Medicine and AMCH can be found here:

https://www.helsinki.fi/en/faculty-of-medicinehttps://www.helsinki.fi/en/meilahti-campus

Faculty of Medicine, Jackson laboratory, invites applications for a position of Doctoral Student / Research Assistant in mitochondrial biology and signalling for a fixed-term

The focus of the lab is to unravel fundamental signalling pathways and mechanisms controlling mitochondrial function. We are particularly interested in how mitochondria adapt signalling to metabolic cues in models of dysfunction including primary mitochondrial patient cell lines, cancer and associated disorders. We aim to exploit this knowledge on basic principles of mitochondrial signalling and subsequent metabolic susceptibilities in cellular models to help devise novel treatments of diseases that stem from misregulated mitochondrial function.

In this role the candidate will have the unique opportunity to drive an exciting project addressing limiting metabolic pathways in models of mitochondrial dysfunction by genome-wide CRISPR screening and mitochondrial structural analysis. The successful candidate will have access to a wide range of methodologies with work consisting in preparation of cell models, construction of libraries, and analysis of metabolic, proteomic and microscopic data at the cellular level.

We are looking for a highly motivated independent researcher with prime analytical skills driven by a passion for science. We expect you to formulate your own hypotheses, propose experimental design to address them, and take advantage of the laboratory and research communitys intellectual and skill resources to advance the knowledge of the field. The appointee is expected to publish in top-level international peer reviewed scientific journals. In addition, she/he is also expected to potentially take part on the other research tasks such as ones related to ongoing studies and preparation of grant applications. The specific responsibilities will vary according to the level of expertise of the candidate.

The ideal candidate has an extensive background in standard molecular cell biological methods, ideally encompassing genetic and microscopic techniques and/or bioinformatics (NGS data). Expertise in biochemistry and molecular biology is a pre-requisite for this position. Additional expertise for research projects involving human subjects, primary cell culture would be highly desirable. The ideal candidate is an adaptable team-player and has excellent communication and organizational skills and a strong command in written and spoken English and should be familiar with the constraints related to translational research.

This position will provide multiple opportunities for collaborations with potential lab visits abroad and cross-disciplinary scientific exchange, where the candidate will receive extensive training in cutting-edge technology. An aptitude to drive and maintain intra and inter team collaborations will be highly appreciated. In return, the candidate is offered access to an extensive variety of methodology and advanced techniques, appropriate supervision and help in career development.

More information about the lab, including the latest research and news, can be found here:http://www.jacksonlab.org

The position is initially limited to 2 years with a possibility of extension starting from September 2020. The contract of employment includes a probationary period of 6 months. Salary will be based on the Universities salary scheme for teaching and research personnel composed of both task specific and personal performance components.

The position will remain open until a suitable candidate will be recruited.

Please submit: CV, list of publications, motivation letter including a description of your research interests, and the names and telephone numbers of at least two referees.

Please submit your application, together with the required attachments, through the University of Helsinki electronic recruitment system by clicking on the Apply for job button. Internal applicants (i.e., current employees of the University of Helsinki) submit their applications through the SAP HR portal.

For further information, please contact Christopher B. Jackson, Ph.D., docent:christopher.jackson@helsinki.fi

Due date

31.08.2020 23:59 EEST

Go here to read the rest:
Doctoral Student/Research Assistant in Mitochondrial Biology and Signalling job with UNIVERSITY OF HELSINKI | 218596 - Times Higher Education (THE)

These Unusual Metallic Blue Fruits Have Incredible Dazzling Color Now Scientists Know How and Why – SciTechDaily

Viburnum tinus owes the dazzling blue colour of its fruit to fat in its cellular structure, the first time this type of colour production has been observed in nature. Credit: Rox Middleton

Researchers have found that a common plant owes the dazzling blue color of its fruit to fat in its cellular structure, the first time this type of color production has been observed in nature.

The plant, Viburnum tinus, is an evergreen shrub widespread across the UK and the rest of Europe, which produces metallic blue fruits that are rich in fat. The combination of bright blue color and high nutritional content make these fruits an irresistible treat for birds, likely increasing the spread of their seeds and contributing to the plants success.

The researchers, led by the University of Cambridge, used electron microscopy to study the structure of these blue fruits. While there are other types of structural color in nature such as in peacock feathers and butterfly wings this is the first time that such a structure has been found to incorporate fats, or lipids. The results are reported in the journal Current Biology.

Viburnum tinus plants can be found in gardens and along the streets all over the UK and throughout much of Europe most of us have seen them, even if we dont realize how unusual the color of the fruits is, said co-first author Rox Middleton, who completed the research as part of her Ph.D. at Cambridges Department of Chemistry.

Closeup of viburnum tinus. Credit: Rox Middleton

Most colors in nature are due to pigments. However, some of the brightest and most colorful materials in nature such as peacock feathers, butterfly wings and opals get their color not from pigments, but from their internal structure alone, a phenomenon known as structural color. Depending on how these structures are arranged and how ordered they are, they can reflect certain colors, creating color by the interaction between light and matter.

I first noticed these bright blue fruits when I was visiting family in Florence, said Dr. Silvia Vignolini from Cambridges Department of Chemistry, who led the research. I thought the color was really interesting, but it was unclear what was causing it.

The metallic sheen of the Viburnum fruits is highly unusual, so we used electron microscopy to study the structure of the cell wall, said co-first author Miranda Sinnott-Armstrong from Yale University. We found a structure unlike anything wed ever seen before: layer after layer of small lipid droplets.

The lipid structures are incorporated into the cell wall of the outer skin, or epicarp, of the fruits. In addition, a layer of dark red anthocyanin pigments lies underneath the complex structure, and any light that is not reflected by the lipid structure is absorbed by the dark red pigment beneath. This prevents any backscattering of light, making the fruits appear even more blue.

Microscopy view of Viburnum tinus. Credit: Rox Middleton

The researchers also used computer simulations to show that this type of structure can produce exactly the type of blue color seen in the fruit of Viburnum. Structural color is common in certain animals, especially birds, beetles, and butterflies, but only a handful of plant species have been found to have structurally colored fruits.

While most fruits have low fat content, some such as avocadoes, coconuts and olives do contain lipids, providing an important, energy-dense food source for animals. This is not a direct benefit to the plant, but it can increase seed dispersal by attracting birds.

The color of the Viburnum tinus fruits may also serve as a signal of its nutritional content: a bird could look at a fruit and know whether it is rich in fat or in carbohydrates based on whether or not it is blue. In other words, the blue color may serve as an honest signal because the lipids produce both the signal (the color) and the reward (the nutrition).

Honest signals are rare in fruits as far as we know, said Sinnott-Armstrong. If the structural color of Viburnum tinus fruits are in fact honest signals, it would be a really neat example where color and nutrition come at least in part from the same source: lipids embedded in the cell wall. Weve never seen anything like that before, and it will be interesting to see whether other structurally colored fruits have similar nanostructures and similar nutritional content.

One potential application for structural color is that it removes the need for unusual or damaging chemical pigments color can instead be formed out of any material. Its exciting to see that principle in action in this case the plant uses a potentially nutritious lipid to make a beautiful blue shimmer. It might inspire engineers to make double-use colors of our own, said Vignolini.

Reference: Viburnum tinus Fruits Use Lipids to Produce Metallic Blue Structural Color by Rox Middleton, Miranda Sinnott-Armstrong, Yu Ogawa, Gianni Jacucci, Edwige Moyroud,Paula J. Rudall, Chrissie Prychid, Maria Conejero, Beverley J. Glover, Michael J. Donoghue and Silvia Vignolini, 6 August 2020, Current Biology.DOI: 10.1016/j.cub.2020.07.005

The research was supported in part by the European Research Council, the EPSRC, the BBSRC and the NSF.

Read more:
These Unusual Metallic Blue Fruits Have Incredible Dazzling Color Now Scientists Know How and Why - SciTechDaily

More than 40-year-old cancer mystery solved: Thanks to epigenetics – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Aug 12 2020

In an article that was just published in Proceedings of the National Academy of Sciences (PNAS) by the group of Dr. Manel Esteller, is solved this mystery by describing that in cancer cells the protein that generates the nucleotide "Y" is epigenetically inactivated, causing small but highly aggressive tumors.

Before the first oncogene mutations were discovered in human cancer in the early 1980s, the 1970s provided the first data suggesting alterations in the genetic material of tumors. In this context, the prestigious magazine "Nature" published in 1975 the existence of a specific alteration in the transformed cell: an RNA responsible for carrying an amino acid to build proteins (transfer RNA) was missing a piece, the enigmatic nucleotide "Y".

After that outstanding observation, the most absolute silence and ignorance has reigned for forty-five years on the causes and consequences of not having that correct base in that RNA.

In an article that was just published in Proceedings of the National Academy of Sciences (PNAS) by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Professor of Genetics at the University of Barcelona is solved this mystery by describing that in cancer cells the protein that generates the nucleotide "Y" is epigenetically inactivated, causing small but highly aggressive tumors.

Since the original discovery in 1975, there has been much biochemical work to characterize the enzymes involved in the different steps that lead to the desired nucleotide "Y", a hypermodified guanine, but without connecting this characterization with its defect in tumor biology. We have built the bridge between these two worlds by demonstrating that the epigenetic silencing of the TYW2 gene is the cause of the loss of the elusive nucleotide "Y".

Epigenetic blockade TYW2 gene occurs mainly in colon, stomach and uterine cancer. And it has undesirable consequences for healthy cells: the postman (RNA) that sends the signal to produce the bricks of our body (proteins) begins to accumulate errors and the cell takes on a different appearance, far from the normal epithelium, which we call mesenchymal and which it is associated with the appearance of metastasis. In this regard, when we study patients with colon cancer in early stages, the epigenetic defect of TYW2 and the loss of the nucleotide "Y" is associated with those tumors that, although small in size, already lead to less survival of the person. We would like to explore now how to restore the activity of the TYW2 gene and restore the longed-for "Y" piece in cancer in order to close the cycle of this story that began so brilliantly in 1975, at the dawn of modern molecular biology."

Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Professor of Genetics at the University of Barcelona

Source:

Journal reference:

Rossell-Tortella, M., et al. (2020) Epigenetic loss of the transfer RNA-modifying enzyme TYW2 induces ribosome frameshifts in colon cancer. PNAS. doi.org/10.1073/pnas.2003358117.

Read more:
More than 40-year-old cancer mystery solved: Thanks to epigenetics - News-Medical.Net

Global Track Etched Membrane Market : Industry Analysis and Forecast (2019-2026) by Product Type, Material, Application, End User, and Region. -…

Global Track Etched Membrane Market was valued US$ 250.00 Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a XX % CAGR of around during a forecast period.

Request For View Sample Report Page :@ https://www.maximizemarketresearch.com/request-sample/16637/

Rising manufacturing of generic drugs and growing research of the developments of biological molecules, growing adoption of track-etched membrane market in various applications such as healthcare, fuel cells, telecommunication, and transportation, and rising applications in pharmaceutical and biopharmaceutical industries for research will boost the market of track-etched membrane in forecast period.

The report covers the segments in the track etched membrane market such as product type, material, application, and end-user. Based on product type, the Membrane filter segment is expected to hold the largest share of the market during the forecast period due to applicability of membrane filters in final filtration, sample preparation, filtration of aqueous and organic solutions.

By application, Cell biology is estimated to hold the largest market of the track-etched membrane during the forecast period due to rising applications in pharmaceutical and biopharmaceutical industries for research.

In terms of end-user, Pharmaceutical and biopharmaceutical industries are estimated to hold the largest share of the market in the forecast period due to the rising manufacturing of generic drugs and growing research on the developments of biological molecules.

Region-wise, North America estimated to holds the largest share of the track etched membrane market in the forecast period due to rising adoption of laboratory equipment and growing health & environmental concerns. Followed by Europe, Asia Pacific, South America, and Middle East & Africa. The track- etched membrane market in South America and Middle East & Africa is expected to expand because of an increase in health care expenditure and expansion in the health care industry during the forecast period.

Do Inquiry Before Purchasing Report Here: @ https://www.maximizemarketresearch.com/inquiry-before-buying/16637/

The objective of the report is to present a comprehensive analysis of the Global Track Etched Membrane Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Track Etched Membrane Market dynamics, structure by analyzing the market segments and project the Global Track Etched Membrane Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Track Etched Membrane Market make the report investors guide.Scope of Report Track Etched Membrane Market:

Global Track Etched Membrane Market, by Product Type

Membrane filter Capsule & cartridge filter Cell culture insertGlobal Track Etched Membrane Market, by Material

Polycarbonate PolyimideGlobal Track Etched Membrane Market, by Application

Cell biology Micrology Analytical testing OthersGlobal Track Etched Membrane Market, by End User:

Food & beverage Academic & research institute Pharmaceutical and biopharmaceutical industries OthersGlobal Track Etched Membrane Market, by Region

North America Europe Asia Pacific Middle East & Africa Latin AmericaKey Players in Global Track Etched Membrane Market

GE Healthcare Danaher Corning Merck it4ip Sterlitech Oxyphen Sarstedt BRAND GMBH Sartorius SABEU Zefon International GVS Thermo Fisher Scientific Eaton Greiner Bio-One MaCHEREY-NAGEL Avanti Lipids Polar SKC Advantec Avestin Scaffdex Merck KGaA Graver Technologies

Major Table of Contents Report

Chapter One: Track Etched Membrane Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Track Etched Membrane Market Competition, by Players

Chapter Four: Global Track Etched Membrane Market Size by Regions

Chapter Five: North America Track Etched Membrane Revenue by Countries

Chapter Six: Europe Track Etched Membrane Revenue by Countries

Chapter Seven: Asia-Pacific Track Etched Membrane Revenue by Countries

Chapter Eight: South America Track Etched Membrane Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Track Etched Membrane by Countries

Chapter Ten: Global Track Etched Membrane Market Segment by Type

Chapter Eleven: Global Track Etched Membrane Market Segment by Application

Chapter Twelve: Global Track Etched Membrane Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Track Etched Membrane Market Report at: https://www.maximizemarketresearch.com/market-report/global-track-etched-membrane-market/16637/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: Maximize Market Research Pvt. Ltd.

Email: sales@maximizemarketresearch.com

Contact: +919607065656 / +919607195908

Website: http://www.maximizemarketresearch.com

Continue reading here:
Global Track Etched Membrane Market : Industry Analysis and Forecast (2019-2026) by Product Type, Material, Application, End User, and Region. -...

Pregnancy Test for Water Delivers Fast, Easy Results on Water Safety and Quality – SciTechDaily

Tests glow green when they detect a contaminant. Credit: Northwestern University

Handheld platform technology uses single sample to test for a variety of contaminants.

A new platform technology can assess water safety and quality with just a single drop and a few minutes.

Likened to a pregnancy test, the handheld platform uses one sample to provide an easy-to-read positive or negative result. When the test detects a contaminant exceeding the EPAs standards, it glows green.

Led by researchers at Northwestern University, the tests can sense 17 different contaminants, including toxic metals such as lead and copper, pharmaceuticals, cosmetics and cleaning products. The platform which is powered by cell-free synthetic biology is so flexible that researchers can continually update it to sense more pollutants.

Professor Julius Lucks explains how to use ROSALIND. Credit: Northwestern University

Current water tests rely on a centralized laboratory that contains really expensive equipment and requires expertise to operate, said Northwesterns Julius Lucks, who led the study. Sending in a sample can cost up to $150 and take several weeks to get results. Were offering a technology that enables anyone to directly test their own water and know if they have contamination within minutes. Its so simple to use that we can put it into the hands of the people who need it most.

The research will be published today (July 6, 2020) in the journal Nature Biotechnology. Lucks is a professor of chemical and biological engineering in Northwesterns McCormick School of Engineering and a member of the Center for Synthetic Biology. Jaeyoung Jung and Khalid Alam, members of Lucks laboratory, are co-first authors of the paper.

A major challenge of ensuring water quality is that people typically cant see or taste contaminants. Northwesterns platform uses synthetic biology to sense this unnoticeable contamination, filling in the gaps where human senses fall short.

In cell-free synthetic biology, researchers take the molecular machinery including DNA, RNA and proteins out of cells, and then reprogram that machinery to perform new tasks. The idea is akin to opening the hood of the car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car. In this case, Lucks team used molecular machinery from bacterial cells.

Nature has already solved this problem, Alam said. Biology has spent over three billion years evolving an elegant solution to detect contaminants.

We found out how bacteria naturally taste things in their water, Lucks added. They do so with little molecular-level taste buds. Cell-free synthetic biology allows us to take those little molecular taste buds out and put them into a test tube. We can then re-wire them up to produce a visual signal. It glows to let the user quickly and easily see if theres a contaminant in their water.

These reprogramed taste buds are freeze-dried to become shelf-stable and put into test tubes. Adding a drop of water to the tube and then flicking it sets off a chemical reaction that causes the freeze-dried pellet to glow in the presence of a contaminant.

The magic is in the tubes, Lucks said. We compose everything and freeze dry it the same process as making astronaut ice cream.

Lucks and his team call this testing platform RNA output sensors activated by ligand induction. But his team has nicknamed it ROSALIND for short, in honor of famed chemist Rosalind Franklin, who discovered the DNA double helix alongside James Watson and Francis Crick. Franklins 100th birthday would have been next month (July 25).

Her work essentially eventually enabled us to learn how to reprogram DNA to act in our technology, Lucks said.

When starting this project, Lucks took inspiration from another woman scientist in his life: his wife, Northwestern anthropologist Sera Young, who studies global food and water security and the role of household water insecurity in societal well-being.

Sera researches how poor water quality impacts peoples daily lives, Lucks said. People tend to go to the most convenient sources to get water. But if they knew that water was contaminated, they might choose to travel farther to find safer water. We want everyone to have the tools they need in order to make informed decisions.

To test the new platform in the field, Lucks, Jung, Alam and fellow Northwestern professor Jean-Francois Gaillard visited Paradise, California at the end of last year. One year earlier, a string of massive wildfires obliterated the northern California town, destroying nearly 19,000 buildings and displacing most of its population. Gaillard, a professor of environmental engineering, is an expert in the biogeochemical processes that affect metals in the aquatic system.

Wildfires basically melted the town, Lucks said. They burned down buildings and melted cars that released toxic metals into the environment.

Lucks, Gaillard and their teams tested ROSALIND alongside gold-standard water tests and discovered that ROSALIND was able to identify the presence of elevated toxic metals in the water supply. It also provided much faster and less expensive results.

Lucks and his team envision that ROSALIND could help recovery efforts like the one in Paradise, in which residents needed to perform tens of thousands of tests in order to know if their community was safe to re-enter.

Laboratory testing doesnt scale, Alam said. It shouldnt take days to get an answer to the simple question: Is my water safe to drink?'

Disasters, of course, arent the only causes of unsafe water. Heavy metals, such as copper and lead, that are naturally found in the environment can leech into pipes, contaminating household water taps and school drinking fountains. Personal care products, such as sunscreens and lotions, wash off peoples skin and end up in waterways. Unused pharmaceuticals and agricultural herbicides, too, run off into our water and end up in our sinks.

But, unless we can directly and regularly test for these pollutants, theres no way to maintain a peace of mind.

When testing water in their own home in Evanston, Illinois, Lucks and Young noted several difficulties. Consuming high levels of copper over many months or years can lead to liver damage and even death. With this concern, Lucks decided to check the copper levels in their household water. It cost $150 and took a month to receive the results.

This is a one-time test, Lucks said. It doesnt allow for checking levels from different taps in the house or temporal testing over time.

Testing for lead wasnt much easier. Lead-testing kits are available at most hardware stores. But after filling a tube with water, it still must be mailed to a centralized facility. It still costs up to $150 per test and takes weeks for results. And if people want to check their water for other contaminants, such as antibiotics, tests simply do not exist for consumers.

There has been a lot of advances in developing point-of-use diagnostics for monitoring pathogens, Jung said. But not nearly enough effort for detecting chemical contaminants.

To ensure access to safe and clean drinking water, we need technologies that will allow easy monitoring of water quality, Lucks said. With a simple, easy-to-use, handheld device like ROSALIND, you can test the water in your home or out in the field where you would want to use it most.

###

Reference: Cell-free biosensors for rapid detection of water contaminants 6 July 2020, Nature Biotechnology.DOI: 10.1038/s41587-020-0571-7

The research, Cell-free biosensors for rapid detection of water contaminants, was supported by the National Science Foundation (award numbers 1452441 and 1929912), the National Institutes of Health (award number R35 GM118157), the Crown Family Center for Jewish and Israel Studies at Northwestern University and Searle Funds at The Chicago Community Trust.

Editors note: Northwestern startup company, Stemloop, has optioned the ROSALIND technology with plans to commercialize it. Lucks, Alam and Northwestern will have financial interests (royalties, equities), if it is commercialized.

See original here:
Pregnancy Test for Water Delivers Fast, Easy Results on Water Safety and Quality - SciTechDaily

New nanomedicines for mRNA therapeutics in breast cancer and heart failure – Mirage News

TAU researcher Prof. Dan Peer, from the school of Molecular Cell Biology and Biotechnology, is one of 11 partners in the international project EXPERT that has been awarded a total of 14.9 million EUR from the EU Horizon 2020. The project is working to find efficient ways to deliver protein coding mRNA by using various nanoparticles for the treatment of breast cancer and myocardial infarction, which are two of the most pressing health challenges in European society today.

Prof. Dan Peer, Director, Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences and Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University Center for Nanoscience and Nanotechnology and Tel Aviv University Cancer Biology Research Center.

It is about developing mRNA therapy for the treatment of breast cancer. Much of it involves testing different methods to improve the delivery of mRNA to cells in vivo. These methods are fundamentally based either on lipid nanoparticles (LNPs), biological nanoparticles called exosomes, or cell penetrating peptides (CPPs). In addition to this, we intend to analyze what these nanoparticles bind to in biological fluids in order to better understand what drives uptake in specific cells types.

Our lab was the first to show systemic, cell specific delivery of mRNA molecules that express therapeutic proteins in designated cells. We will further develop our ASSET platform for cell specific targeting of lipid nanoparticles to achieve improved delivery of therapeutic mRNAs and optimize formulations that enable systemic administration in different preclinical models. Part of the work will also consist of understanding how nanoparticle surfaces bind to host factors in blood and how this can affect the uptake of nanoparticles.

We will now see how these delivery methods work side by side in cell culture and animal models. The hope is then to be able to deliver an mRNA cocktail with one of the aforementioned vectors for the treatment of triple-negative breast cancer. In parallel, these vectors will also be evaluated for delivery of VEGF mRNA in the treatment of myocardial infarction.

Read more here:
New nanomedicines for mRNA therapeutics in breast cancer and heart failure - Mirage News

AstroDancing With The Stars – Astrobites

Title: AstroDance: Engaging Deaf and Hard-of-Hearing Students in Astrophysics via Multimedia Performances

Authors: J. Nordhaus, M. Campanelli, J. Bochner, T. Warfield, H.-P. Bischof, J. Noel-Storr

First authors institution: Rochester Institute of Technology

Journal: Open Access here

Deaf and hard-of-hearing (DHH) students commonly come into and out of the classroom knowing less content than their hearing classmates (Marschark et al. 2008). As a direct consequence, DHH students earn STEM bachelor degrees at lower rates than their hearing classmates (15% DHH vs. 25% hearing); this in turn causes the DHH community to be underrepresented in STEM fields as a whole. It is important that we, as a scientific community, make science accessible and scientific careers attainable to all. One such method of making astronomy more inclusive to the DHH community is AstroDance!

What is AstroDance?

Created by a team of astrophysicists, science educators, dancers, computer programmers, and choreographers, AstroDance is a multi-media performance that incorporates both signed and visual components. Based largely around gravitational wave astronomy, each scientific section of this program starts with a short story narrated in English and American Sign Language (ASL) and is then followed by an interpretive dance with music and scientifically accurate images projected on the back of the stage. These images were largely taken from scientific work done by members of the Center for Computational Relativity and Gravitation at the Rochester Institute of Technology. See the video below from the authors of this paper summarizing their work and showing clips from a performance. AstroDance first premiered at the Little Theater in Rochester, NY as part of the Fringe Festival in 2012. Following this premiere was a year-long, 20-stop tour around the Northeastern states of the US.

What did audiences take away?

After each show, attendees were asked to complete a brief anonymous survey about their experience. In addition to demographic information {age, (binary) gender, race/ethnicity, & hearing status}, the survey asked participants to rate their enjoyment of the program, how much science they learned, and how much they participated in other science activities. Finally, survey participants were asked to describe the performance, share what they learned, and whether they had any comments.

Of the ~20 performances of AstroDance, 971 survey responses were collected. Though only binary gender options were presented, of the 971 responses, there were roughly equal numbers of boys/men and girls/women. 89% (866) participants offered ethnicity data (see Fig. 1 for a pie chart); all non-white ethnicity percentages are above the national average! Shown in Figure 2 is the distribution of hearing status of audience members by age. There were roughly equal numbers of DHH members as there were hearing.

When analyzing results from the scaled questions, the authors of todays paper enlisted an age cutoff of 22 years, as they expect a large majority of those responses are from students. The results from these three (3) questions are shown in Figure 3. Both the hearing and DHH groups equally enjoyed the performances, but the DHH group significantly learned more science from the performances and participated in more science related activities (p-values of 0.001 and 0.00001, respectively).

When analyzing the responses to the free-response questions, the authors chose to present a few representative responses for each in the paper. When asked how they might describe the performance to a friend or colleague, many of the responses said that this performance was a positive and complementary blend of art and science. A shared response was:

Different from regular performances I normally attend. There was narration, sign language interpretative audience interaction/participation, glow in the dark props. Yes, I learned that scientists and artists can work together to collaborate ideas/views.

Continuing on with the other free-response questions, when asked to explain something they had learned from the performance, many talked about the astrophysical objects taught in the show such as black holes and gravitational waves. The last free-response question allowed survey takers to leave any comments. The authors of the paper provided two given responses: This is great, creative, beautiful and didactic > do something please about cell biology and Artistic expression is a great way to teach an understanding of complex. scientific concepts. Beautiful costume design & props. Love the body movements forms!

What did AstroDance show?

Although dance is not usually someones idea of what science communication can be, this program has shown that it not only can be, but perhaps should be! The agreement between DHH and hearing students that they enjoyed the performances and learned a lot of science shows that AstroDance is an inclusive and effective science communication tool! The fact that DHH students learned more science than their hearing schoolmates highlights the importance of a program like AstroDance even more, as it shows that it was especially effective at engaging DHH audience members. Its important that we, as a scientific community, take every approach to make science accessible to all, especially by trying unconventional methods. AstroDance has offered us one way to make science, especially astronomy, more inclusive to the DHH community. I am excited to what AstroDance inspires us all to become!

About Huei SearsHuei Sears (she/her/hers) is a second-year graduate student at Ohio University studying astrophysics! Her research is focused on Gamma-Ray Burst host galaxies & how they fit into the mass-metallicity relationship. Previously she was at Michigan State University searching for the elusive period of B[e] supergiant, S18. In addition to research, she cares a lot about science communication, and is always looking for ways to make science more accessible. In her free time, she enjoys going to the gym, baking a new recipe, listening to Taylor Swift, watching the X-Files, and spending time with her little sister.

Read this article:
AstroDancing With The Stars - Astrobites

There’s a Weird Structure in Our Inner Ears That Hardly Anybody Talks About – ScienceAlert

Deep inside your ear there's a tiny thing you may not know about - a dead-end tube called an endolymphatic sac. Details on its function have been debated, but it was only in 2018 that scientists figured out (at least in part) what this odd structure is for.

According to a chance discovery in zebrafish, the endolymphatic sac may play the role of some kind of 'safety valve' in the inner ear.

The story behind the find starts several years ago when Harvard Medical School systems biologist Ian Swinburne made a connection between a pulsating blob of cells in a developing zebra fish and that cul-de-sac thing poking out of our own inner ear.

If you missed seeing it on your high school biology exam, don't worry about it. You won't often find the endolymphatic sac on diagrams of the inner ear; possibly because none of us know what it actually does.

Imagine your inner ear as a long tube shaped like a weird snail. At one end, it curls into a shell-like structure called a cochlea. At the other where the snail's eyes would be there are three perpendicular loops called a labyrinth.

Fluid in the snail-shell part transfers waves we interpret as sound, while the fluid in the loops acts like a biological spirit-level, sloshing about to tell you which way is up.

Between these two structures, behind the window where a tiny hearing bone called the stapes plugs in, there are two chambers called the utricle and the saccule. These chambers in turn connect to a short, thin tube ending in that mysterious sac. Try to picture it hidden behind the diagram below:

Diagram of the inner ear, missing some bits. (7activestudio)

While nobody is certain about what it does, there are some clues. It's understood to have a starring role in Mnire disease, a condition characterised by symptoms that include vertigo and tinnitus.

The disease is presumed to be caused by excess fluid in the inner ear overinflating the structure, and since surgery on the endolymphatic sac has been shown to help alleviate symptoms, the sac probably has something to do with fluid regulation.

Circumstantial evidence is a good place to start, but Swinburne and his zebrafish offered an opportunity to do a compare and contrast on this weird bubble of tissue.

Watching the endolymphatic sac at work inside something as dense as a human head is easier said than done.But in the zebra fish, Swinburne could use dyes to watch and record the movement of fluid slowly flow in and then quickly out of the tiny structure.

There was just one question.

"We had all these movies where you could see the whole structure pulsing, and when Ian injected dye into the sac we could see fluid flowing out," said Swinburne's postdoctoral advisor Sean Megason back in June 2018.

"But it wasn't clear how that fluid was getting out. It seemed like something weird was going on."

Then, the team got lucky. In a separate zebrafish study, a mutant fish with a variation of a certain genetic regulator happened to have an endolymphatic sac that was larger than usual.

Whatever this mutated gene did, it seemed to cause the structure to overfill and fail to deflate properly, hinting at a structural difference that might show how a normal sac works.

Using high-resolution electron micrographs the researchers found their answer. Inside the sac there were overlapping, flap-like projections called lamellae poking out of the cells.

"Biologists like to say that structure determines function," said Swinburne."When we saw the lamella for the first time, it all clicked."

The cells lining the endolymphatic sac appear to have spaces between them to allow fluid to pass. Those lamellae plug the gaps, but as the pressure builds they slide apart, until suddenly the whole sac can leak like a sieve.

A closer look using more advanced microscopy techniques showed that this was indeed what was happening.

"It looks like a cell that's migrating, but they are part of the epithelium. It's really weird cell biology," said Swinburne.

For people who suffer problems maintaining the balance of fluid in their inner ear, new information about the endolymphatic sac's role as a pressure release valve could one day come in handy.

And just maybe we can finally add it into those anatomy text books.

This research was published in eLife.

A version of this article was first published in June 2018.

Continued here:
There's a Weird Structure in Our Inner Ears That Hardly Anybody Talks About - ScienceAlert